Concord Biotech announced the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation facility. The inspection took place from 18 June 2026 to 24 June 2026, and was concluded successfully.